NRG-GU011 : A Phase II Double-Blind, Placebo Controlled Trial of Prostate Oligometastatic Radiotherapy with or without Androgen Deprivation Therapy in Oligometastatic Prostate Cancer (NEO PROMETHEAN)
Principal Investigator
Study Number
STUDY02001610
Summary
This phase II trial tests whether relugolix and radiation therapy works to shrink tumors in patients with prostate cancer that has spread in a limited way to 1 to 5 other parts of the body (oligometastatic). Testosterone can cause the growth of prostate cancer cells. Relugolix lowers the amount of testosterone made by the body. This may help stop the growth of tumor cells that need testosterone to grow. Giving relugolix with radiation therapy may help lower the chance of prostate cancer growing or spreading.
Phase
II
Contact
Available at the following location(s)
- Lebanon
- St. Johnsbury, VT
View more details at ClinicalTrials.gov
Do you need help with some of the labels on this page?
Read our glossary of terms